Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn begins patient enrollment for depressive disorder study
The randomised, double blind and placebo-controlled study will enroll up to 300 patients, and will be conducted at 40 sites across the US. In the study, Serdaxin will
The randomised, double blind and placebo-controlled study will enroll up to 300 patients, and will be conducted at 40 sites across the US. In the study, Serdaxin will
The company will launch the allergy drug in the US as an OTC in March 2011. Sanofi-aventis Global Operations president Hanspeter Spek said leveraging their US Consumer Healthcare
Watson claims that its Colesevelam HCI powder for oral suspension is a generic version of Daiichi Sankyo’s Welchol oral suspension. Colesevelam is indicatred for the reduction of elevated
Exclusivity for PLAVIX in the US is now scheduled to expire on 17 May 2012. According to sanofi-aventis and Bristol-Myers Squibb, PLAVIX has been shown to decrease the
GSK claims that Avodart and its generic counterpart, Dutasteride, are medications that are used to prevent the conversion of testosterone to dihydrotestosterone, or DHT, in a person’s body.
Infarmasa’s portfolio consists of over 600 registered products; of which over 500 are currently marketed and has two manufacturing facilities in Lima. Teva Pharma president and CEO Shlomo
Codexis is a clean technology company that develops of optimized biocatalysts that make industrial processes faster, cleaner and more efficient. As per the pact, DSP will use Codexis’
Before joining Labopharm, Heino held executive positions in a subsidiary of Johnson & Johnson, Centocor. Prior to Centocor, Heino worked with Janssen Pharmaceuticals, also a subsidiary of Johnson
With this acquisition, Actient Pharma is able to offer pharmaceutical, and medical device and diagnostic solutions to the urology community. Actient Pharma CEO Ed Fiorentino said they look
Prior to joining Savient Pharma, Johnson worked as the senior vice president of Eli Lilly and the president of Lilly Oncology Business Unit. Before Eli Lilly, he has